BC Innovations | Aug 3, 2018
Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
BC Innovations | Jul 12, 2018
Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
BC Innovations | May 15, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a chemokine-targeting single-chain variable fragment (scFv)-based fusion protein that could help treat arthritis. Screening of a scFv library for binding to various human and mouse chemokines, engineering...
BC Innovations | Nov 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
BC Innovations | May 8, 2017
Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and glycosaminoglycans containing...
BC Innovations | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BC Innovations | Nov 9, 2016
Distillery Therapeutics

Cancer

INDICATION: Leukemia Mouse studies suggest inhibiting signaling between CCL3 and its receptors, CCR1 and CCR5 , could help treat juvenile myelomonocytic leukemia (JMML) in Noonan syndrome patients harboring activating SHP-2 mutations. In a mouse model of...
BC Week In Review | Sep 5, 2016
Clinical News

VBI Vaccines preclinical data

In an ex vivo model of CMV-positive GBM, VBI-1901 recruited and activated dendritic cells as measured by induction of interleukin-8 (IL-8; CXCL8 ) and macrophage inflammatory protein-1 alpha ( CCL3 ; MIP1A ). The product is a...
BC Extra | Apr 19, 2016
Clinical News

Predictive biomarkers linked to cytokine release syndrome

Researchers led by David Teachey at the Children's Hospital of Pennsylvania and University of Pennsylvania think they have identified the first predictive biomarkers of severe cytokine release syndrome (CRS) in patients undergoing chimeric antigen receptor...
BC Extra | Mar 13, 2015
Company News

Newco Annias debuts with glioblastoma vaccine

Immuno-oncology newco Annias Immunotherapeutics Inc. (Chapel Hill, N.C.) debuted with IP licensed from Duke University to a clinical-stage vaccine that targets solid tumors and a method to boost the vaccine's activity. CEO Reiner Laus told...
Items per page:
1 - 10 of 19